Acute Gonococcal Urethritis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute gonococcal urethritis. 2 active patents protecting 2 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
2
Active US patents
78/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Gonococcal Urethritis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Pfizer) 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute gonococcal urethritis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
27
1
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Suprax
CEFIXIME
 — 1 75 — 2028-12-14
Vibramycin
doxycycline
 Generic (originally Pfizer) 1 80 — 2027-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7749532 Vibramycin method of use 80 2027-12-19
9233112 Suprax method of use 75 2028-12-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9233112 Suprax method of use 75 2028-12-14
7749532 Vibramycin method of use 80 2027-12-19

Related